Acumen Pharmaceuticals is expected to report zero revenue and a consensus loss of $0.43 per share, with the current stock price of $2.05 significantly trailing the average analyst price target of $7.25.
The primary focus for investors is the company’s cash runway and upcoming clinical updates regarding its lead Alzheimer’s candidate, sabirnetug (ACU193).
Market participants are specifically awaiting topline data from the Phase 2 ALTITUDE-AD trial, which is anticipated in late 2026. Management is also expected to provide updates on the transition to a subcutaneous formulation and long-term funding stability during the earnings call.